AR125815A1 - Composiciones farmacéuticas que comprenden anticuerpos biespecíficos que se unen a b7h4 y cd3 - Google Patents
Composiciones farmacéuticas que comprenden anticuerpos biespecíficos que se unen a b7h4 y cd3Info
- Publication number
- AR125815A1 AR125815A1 ARP220101222A ARP220101222A AR125815A1 AR 125815 A1 AR125815 A1 AR 125815A1 AR P220101222 A ARP220101222 A AR P220101222A AR P220101222 A ARP220101222 A AR P220101222A AR 125815 A1 AR125815 A1 AR 125815A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- bind
- polysorbate
- binding
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 title abstract 3
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 2
- 229920000053 polysorbate 80 Polymers 0.000 abstract 2
- 229940068968 polysorbate 80 Drugs 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención se refiere a composiciones farmacéuticas y formas de dosificación unitarias que comprenden anticuerpos que se unen a B7H4 y CD3. La invención además proporciona un uso de las composiciones farmacéuticas y formas de dosificación unitarias para procedimientos terapéuticos, en particular en la terapia contra el cáncer. Reivindicación 1: Una composición farmacéutica que comprende que comprende: a) un anticuerpo que comprende una región de unión a antígenos capaz de unirse a B7H4 humana y una región de unión a antígenos capaz de unirse a 5 CD3 humana, b) un agente amortiguador: en donde el pH de la composición es de entre 4,0 a 8,0. Reivindicación 10: Una composición farmacéutica de acuerdo con la forma de realización 9 o 10, en donde el tensioactivo es un polisorbato, opcionalmente en donde el tensioactivo es un polisorbato 20 u 80, preferiblemente polisorbato 80. Reivindicación 59: Un método para preparar la composición farmacéutica como se define en una cualquiera de las formas de realización 1 - 47, que comprende las etapas de mezcla en agua para su inyección: a) 0,5 a 120 mg/ml del anticuerpo, y b) un agente amortiguador y ajustar el pH a 4,0 - 8,0, preferiblemente a 5,0 - 6,0.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185762P | 2021-05-07 | 2021-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125815A1 true AR125815A1 (es) | 2023-08-16 |
Family
ID=81974983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101222A AR125815A1 (es) | 2021-05-07 | 2022-05-09 | Composiciones farmacéuticas que comprenden anticuerpos biespecíficos que se unen a b7h4 y cd3 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4334359A1 (es) |
| KR (1) | KR20240004949A (es) |
| CN (1) | CN117396509A (es) |
| AR (1) | AR125815A1 (es) |
| AU (1) | AU2022268652A1 (es) |
| BR (1) | BR112023021089A2 (es) |
| CA (1) | CA3214582A1 (es) |
| IL (1) | IL308300A (es) |
| WO (1) | WO2022234146A1 (es) |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| AU2003209446B2 (en) | 2002-03-01 | 2008-09-25 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| ATE514717T1 (de) | 2002-07-18 | 2011-07-15 | Merus B V | Rekombinante produktion von antikörpermischungen |
| AU2004255216B2 (en) | 2003-07-01 | 2010-08-19 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
| AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| KR101799337B1 (ko) | 2007-06-21 | 2017-12-20 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이것의 사용 |
| CA2700714C (en) | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| CL2008003526A1 (es) | 2007-11-30 | 2010-01-11 | Medarex Inc | Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer. |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| EP2411407A1 (en) | 2009-03-27 | 2012-02-01 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| MX2012006406A (es) | 2009-12-04 | 2012-07-25 | Genentech Inc | Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos. |
| GEP20166442B (en) | 2010-03-04 | 2016-03-10 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| KR101930964B1 (ko) | 2010-04-20 | 2018-12-19 | 젠맵 에이/에스 | 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법 |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| IL299365A (en) | 2010-05-27 | 2023-02-01 | Genmab As | Monoclonal antibodies against 2HER |
| US9834615B2 (en) | 2010-08-16 | 2017-12-05 | Novimmune Sa | Methods for the generation of multispecific and multivalent antibodies |
| BR112013001847A2 (pt) | 2010-08-24 | 2016-05-31 | Hoffmann La Roche | anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| DK2635607T3 (da) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | Stabilt heterodimert antistofdesign med mutationer i fc-domænet |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| CN104114579B (zh) | 2011-10-27 | 2020-01-24 | 健玛保 | 异二聚体蛋白的生成 |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| SG11201408646VA (en) | 2012-07-06 | 2015-01-29 | Genmab Bv | Dimeric protein with triple mutations |
| WO2014081202A1 (ko) | 2012-11-21 | 2014-05-30 | 주식회사 파멥신 | Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물 |
| KR20150127199A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 항-b7-h4 항체 및 면역접합체 |
| UA119646C2 (uk) | 2013-07-05 | 2019-07-25 | Ґенмаб А/С | Гуманізоване антитіло, що зв`язується з сd3 людини |
| KR20180030635A (ko) | 2015-07-15 | 2018-03-23 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| KR102346988B1 (ko) * | 2016-07-26 | 2022-01-03 | 시즈오카켄 | 항 b7-h4 항체 |
| SG11202000387YA (en) | 2017-08-25 | 2020-03-30 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
| WO2019165077A1 (en) * | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| EP3877409A1 (en) * | 2018-11-06 | 2021-09-15 | Genmab A/S | Antibody formulation |
| KR20220047808A (ko) * | 2019-08-15 | 2022-04-19 | 젠맵 에이/에스 | Cd3 및 cd20에 대해 지시된 이중특이적 항체를 포함하는 제약 조성물 및 그의 용도 |
| TW202200624A (zh) * | 2020-03-18 | 2022-01-01 | 丹麥商珍美寶股份有限公司 | 抗體 |
-
2022
- 2022-05-09 CA CA3214582A patent/CA3214582A1/en active Pending
- 2022-05-09 AR ARP220101222A patent/AR125815A1/es unknown
- 2022-05-09 AU AU2022268652A patent/AU2022268652A1/en active Pending
- 2022-05-09 BR BR112023021089A patent/BR112023021089A2/pt unknown
- 2022-05-09 EP EP22728462.7A patent/EP4334359A1/en active Pending
- 2022-05-09 IL IL308300A patent/IL308300A/en unknown
- 2022-05-09 KR KR1020237041813A patent/KR20240004949A/ko unknown
- 2022-05-09 WO PCT/EP2022/062518 patent/WO2022234146A1/en active Application Filing
- 2022-05-09 CN CN202280033116.8A patent/CN117396509A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023021089A2 (pt) | 2023-12-12 |
| CN117396509A (zh) | 2024-01-12 |
| AU2022268652A9 (en) | 2024-02-22 |
| CA3214582A1 (en) | 2022-11-10 |
| IL308300A (en) | 2024-01-01 |
| EP4334359A1 (en) | 2024-03-13 |
| KR20240004949A (ko) | 2024-01-11 |
| AU2022268652A1 (en) | 2023-10-05 |
| WO2022234146A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| CL2020002945A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t | |
| ECSP18043564A (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| CL2022003747A1 (es) | Anticuerpos ccr8 para aplicaciones terapéuticas | |
| CL2008002923A1 (es) | Anticuerpo monoclonal humano aislado porque se adhiere a mesotelina humana; composicion que comprende dicho anticuerpo; conjugado entre anticuerpo y agente terapeutico; molecula de acido nucleico que codifica el anticuerpo; uso para preparar un medicamento para tratar cancer. | |
| ECSP22080714A (es) | Anticuerpos que se unen a b7h4 | |
| AR059922A1 (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| AR053651A1 (es) | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama | |
| CO6150193A2 (es) | Terapia tumoral con anticuerpo anti-vegf | |
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| PE20121397A1 (es) | Anticuerpos especificos para cadherina-17 | |
| CR10996A (es) | Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana | |
| BR112022016643A2 (pt) | Epítopos e anticorpos contra kras | |
| AR082353A1 (es) | Ligando ox40 y de linfopoyetina del estroma timico (tslp) en el cancer | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| PE20212158A1 (es) | Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso | |
| AR125815A1 (es) | Composiciones farmacéuticas que comprenden anticuerpos biespecíficos que se unen a b7h4 y cd3 | |
| BR112022009482A2 (pt) | Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo | |
| CO2022001643A2 (es) | Anticuerpos anti-grp78 y método de uso de los mismos | |
| AR110424A1 (es) | Moléculas de unión a adam9 y métodos de uso de las mismas | |
| CO2023000536A2 (es) | Formas farmacéuticas de maleato de acalabrutinib | |
| CL2023000916A1 (es) | Anticuerpos con capacidad de unirse a ror2 y anticuerpos biespecíficos que se unen a ror2 y cd3. | |
| AR117423A1 (es) | Métodos para tratar cáncer con una combinación de un anticuerpo anti-pd-1 y un conjugado de anticuerpo anti-factor de tejido y una droga |